Table 1 Impacts of implementing SARS-CoV-2 genomics on other research, development and surveillance operations
Area of Impact | Proportion of Laboratories |
|---|---|
SARS-CoV-2 Genomics R&D activities initiated? | |
Yes | 70% |
No | 30% |
Other genomics R&D impacted or paused? | |
High or severe impact | 75% |
Minimal or temporary impact | 25% |
Genomics personnel reassigned from other areas (e.g., foodborne diseases/PulseNet Canada) | |
Yes | 50% |
No | 50% |